Shots:

• Cerianna (Fluoroestradiol F 18) is a novel FDA approved molecular imaging agent targeted for PET imaging for detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer
• The product will also allow the clinicians better guide treatments for metastatic breast cancer patients and improve patients’ QoL
• In late 2020/early 2021 the PETNET Solutions will be responsible for Cerianna (Fluoroestradiol F 18) commercialization while Zionexa will manufacturer and exclusive commercialize it in the US

Click here to read full press release/ article | Ref: Zionexa | Image: Zionexa